<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41699">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01685424</url>
  </required_header>
  <id_info>
    <org_study_id>0663-162</org_study_id>
    <secondary_id>7013.021</secondary_id>
    <secondary_id>EMEA/H/A - 31/632</secondary_id>
    <nct_id>NCT01685424</nct_id>
  </id_info>
  <brief_title>Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)</brief_title>
  <official_title>Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This postmarketing study was conducted to describe prescribing patterns for etoricoxib
      (ARCOXIA®) in General Practice and describe the incidence of selected adverse events
      recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency
      (MHRA) General Practice Research Database (GPRD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Dose of Initial Etoricoxib Prescription</measure>
    <time_frame>At first prescription (during a time period up to 13.75 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Initial Etoricoxib Prescription</measure>
    <time_frame>At first prescription (during a time period up to 13.75 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant's Baseline Characteristics (Demographics and Medical)</measure>
    <time_frame>At first prescription (during a time period up to 13.75 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events of Special Interest Among Etoricoxib Users</measure>
    <time_frame>During a time period up to 13.75 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;Off-label&quot; use of Etoricoxib</measure>
    <time_frame>At first prescription (during a time period up to 13.75 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Gout</condition>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Etoricoxib Prescription (Period 1)</arm_group_label>
    <description>First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib Prescription (Period 2)</arm_group_label>
    <description>First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat Etoricoxib Prescription</arm_group_label>
    <description>One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>As per routine clinical practice in the United Kingdom</description>
    <arm_group_label>Etoricoxib Prescription (Period 1)</arm_group_label>
    <arm_group_label>Etoricoxib Prescription (Period 2)</arm_group_label>
    <arm_group_label>Repeat Etoricoxib Prescription</arm_group_label>
    <other_name>ARCOXIA®)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All participants in the MHRA's Full Feature GPRD (FF-GPRD) who have at least one
        electronic outpatient prescription record for etoricoxib issued by a General Practitioner
        during the period (April 1, 2002 to December 31, 2015) at the date of query execution
        against the FF-GPRD data warehouse.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients in the MHRA's Full Feature GPRD (FF-GPRD) who have at least one
             electronic outpatient prescription record for etoricoxib issued by a General
             Practitioner during the period (April 1, 2002 to December 31, 2015) at the date of
             query execution against the FF-GPRD data warehouse.

        Exclusion Criteria:

          -  Not registered in a GPRD-contributing practice that had continuously

        collected data deemed to be 'up-to-standard' for research purposes from 1 April 2002
        through to 31 December 2015.

          -  Never registered as a permanent patient of a General Practitioner in the practice

          -  Registration details were not acceptable (i.e. incomplete data or logically
             implausible dates)

          -  Not registered with a General Practitioner for at least 365 days before the date that
             the patient's first etoricoxib prescription was recorded in the GPRD
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etoricoxib</keyword>
  <keyword>ARCOXIA</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <keyword>Gout</keyword>
  <keyword>Arthritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Gout</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
